Osimertinib-Induced Cardiomyopathy.
CHF, congestive heart failure
EF, ejection fraction
EGFR, epidermal growth factor receptor
NSCLC, non–small cell lung cancer
TKI, tyrosine kinase inhibitor
cardio-oncology
cardiotoxicity
heart failure
osimertinib
reduced ejection fraction
Journal
JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
19
09
2019
revised:
26
11
2019
accepted:
26
12
2019
entrez:
28
7
2021
pubmed:
1
4
2020
medline:
1
4
2020
Statut:
epublish
Résumé
Osimertinib is the preferred treatment in patients with metastatic non-small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (
Identifiants
pubmed: 34317311
doi: 10.1016/j.jaccas.2019.12.038
pii: S2666-0849(20)30039-5
pmc: PMC8298525
doi:
Types de publication
Case Reports
Langues
eng
Pagination
641-645Informations de copyright
© 2020 The Authors.
Références
Nat Rev Clin Oncol. 2015 Dec;12(12):718-31
pubmed: 26462128
Int J Mol Sci. 2012 Sep 26;13(10):12268-86
pubmed: 23202898
Intern Med. 2017 Aug 15;56(16):2195-2197
pubmed: 28781309
Lancet Oncol. 2016 Dec;17(12):1643-1652
pubmed: 27751847
Drugs Ther Perspect. 2018;34(8):351-357
pubmed: 30631243
J Thorac Oncol. 2017 Oct;12(10):e159-e160
pubmed: 28939147
Br J Pharmacol. 2017 Nov;174(21):3727-3748
pubmed: 27714776
Annu Rev Pharmacol Toxicol. 2004;44:195-217
pubmed: 14744244
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359